Amar Srivastava, MD
Radiation Oncology · Portland, ORNPI 1235549031
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Viewray Technologies Inc at 50.8% of the total. Reporting peaked in 2022 at $2,026 and has fallen 52.2% since, to $969 in 2025. Among radiation oncology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 22 payments — averaging $162.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viewray Technologies Inc$2K
- Elekta, Inc.$1K
- Siemens Medical Solutions USA, Inc.$404
- Novocure Inc.$149
- Telix Pharmaceuticals$33
- Sumitomo Pharma America, Inc.$28
- plus $26 from 1 others
What the payments were for
- Speaking & faculty fees$1,50042%
- Travel & lodging$68119%
- Food & beverage$1,38739%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viewray Technologies Inc | 9 | $1,814 |
| Elekta, Inc. | 5 | $1,114 |
| Siemens Medical Solutions USA, Inc. | 4 | $404 |
| Novocure Inc. | 1 | $149 |
| Telix Pharmaceuticals | 1 | $33 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Myovant Sciences Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,568 in reported general payments places this provider in the 90th percentile of 93 radiation oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pentoxifylline | 18 | $675 |
| Tamsulosin Hcl | 37 | $487 |
| Lidocaine Hcl ViscousLidocaine Hcl | 12 | $374 |
| Gabapentin | 19 | $329 |
| Dexamethasone | 21 | $326 |
| Oxycodone Hcl | 20 | $306 |
| Levothyroxine Sodium | 16 | $286 |
| Ondansetron OdtOndansetron | 11 | $277 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $121 |
| Lorazepam | 12 | $22 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Portland
- Marka CrittendenPortland$20K
- Steven SeungPortland$11K
- Joshua WalkerPortland$9K
- Andrew KeePortland$7K
- Brandon DyerPortland$4K
- Nima NabavizadehPortland$4K
- Re-I ChinPortland$3K
- Akanksha RajeursPortland$2K
- Matthew SolhjemPortland$2K
- Kristina YoungPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.